Kovitz Investment Group Partners LLC Has $195,000 Stock Position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)

Kovitz Investment Group Partners LLC grew its holdings in shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCAFree Report) by 44.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 50,125 shares of the company’s stock after acquiring an additional 15,400 shares during the period. Kovitz Investment Group Partners LLC owned about 0.12% of Verrica Pharmaceuticals worth $195,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. Tower Research Capital LLC TRC increased its position in shares of Verrica Pharmaceuticals by 25.3% during the first quarter. Tower Research Capital LLC TRC now owns 7,966 shares of the company’s stock worth $51,000 after buying an additional 1,608 shares during the period. Two Sigma Investments LP increased its position in shares of Verrica Pharmaceuticals by 3.9% during the fourth quarter. Two Sigma Investments LP now owns 50,820 shares of the company’s stock worth $140,000 after buying an additional 1,927 shares during the period. Bank of New York Mellon Corp increased its position in shares of Verrica Pharmaceuticals by 27.1% during the first quarter. Bank of New York Mellon Corp now owns 14,612 shares of the company’s stock worth $95,000 after buying an additional 3,115 shares during the period. LPL Financial LLC increased its position in shares of Verrica Pharmaceuticals by 18.2% during the fourth quarter. LPL Financial LLC now owns 26,000 shares of the company’s stock worth $72,000 after buying an additional 4,000 shares during the period. Finally, State Street Corp increased its position in shares of Verrica Pharmaceuticals by 2.0% during the first quarter. State Street Corp now owns 231,035 shares of the company’s stock worth $1,874,000 after buying an additional 4,619 shares during the period. Institutional investors own 34.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on VRCA shares. Jefferies Financial Group restated a “buy” rating and issued a $10.00 price target on shares of Verrica Pharmaceuticals in a report on Friday, December 15th. Needham & Company LLC reduced their price target on shares of Verrica Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 10th.

Get Our Latest Stock Analysis on VRCA

Insiders Place Their Bets

In other news, insider Joe Bonaccorso sold 21,580 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $2.93, for a total value of $63,229.40. Following the sale, the insider now owns 103,658 shares of the company’s stock, valued at $303,717.94. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, insider Joe Bonaccorso sold 21,580 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $2.93, for a total value of $63,229.40. Following the sale, the insider now owns 103,658 shares of the company’s stock, valued at $303,717.94. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Perceptive Advisors Llc purchased 456,923 shares of the stock in a transaction dated Monday, December 18th. The stock was acquired at an average cost of $5.41 per share, for a total transaction of $2,471,953.43. Following the transaction, the insider now owns 5,995,906 shares of the company’s stock, valued at $32,437,851.46. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 1,337,691 shares of company stock valued at $7,938,546. Company insiders own 41.50% of the company’s stock.

Verrica Pharmaceuticals Stock Up 5.2 %

Shares of NASDAQ VRCA opened at $5.51 on Monday. The stock has a market capitalization of $231.75 million, a P/E ratio of -5.15 and a beta of 1.89. The company has a 50-day moving average price of $5.65 and a 200-day moving average price of $4.66. Verrica Pharmaceuticals Inc. has a 1 year low of $2.86 and a 1 year high of $8.69. The company has a debt-to-equity ratio of 1.00, a current ratio of 8.06 and a quick ratio of 8.04.

Verrica Pharmaceuticals (NASDAQ:VRCAGet Free Report) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.10). The firm had revenue of $2.92 million for the quarter, compared to the consensus estimate of $1.12 million. Verrica Pharmaceuticals had a negative net margin of 1,507.90% and a negative return on equity of 75.68%. On average, equities research analysts forecast that Verrica Pharmaceuticals Inc. will post -1.41 EPS for the current fiscal year.

Verrica Pharmaceuticals Company Profile

(Free Report)

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts.

Featured Stories

Institutional Ownership by Quarter for Verrica Pharmaceuticals (NASDAQ:VRCA)

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.